文献速递肝病

美国肝硬化与门静脉高压的患病率及预测因素

Prevalence and predictors of cirrhosis and portal hypertension in the United States.
PubMed 文献 · Hepatology · 2025-01-29

基于NHANES 2017-2020数据,美国普通人群肝硬化患病率为2.6%,临床显著门静脉高压患病率为0.98%。代谢功能障碍相关脂肪性肝病(MASLD)患者占美国肝硬化居民的大多数。过量饮酒、慢性丙型肝炎、男性、肥胖、2型糖尿病和高血压与肝硬化风险独立相关。

要点

  • 美国普通人群肝硬化患病率为2.6%,临床显著门静脉高压患病率为0.98%。
  • MASLD肝硬化患病率1.27%,占美国肝硬化居民的大多数。
  • 过量饮酒、慢性丙型肝炎、男性、肥胖、2型糖尿病和高血压与肝硬化风险独立相关(均p<0.05)。

核心结论

  • 美国肝硬化患病率为2.6%,临床显著门静脉高压患病率为0.98%。
  • MASLD个体构成美国肝硬化居民的大多数。

研究设计与样本

  • 使用2017-2020年美国国家健康与营养调查(NHANES)数据估计肝硬化与临床显著门静脉高压的患病率。
  • 肝硬化通过瞬时弹性成像测定的肝硬度值或FIB-4评分评估。
  • 临床显著门静脉高压通过肝硬度值与血小板计数,或在肝硬化存在时使用非选择性β受体阻滞剂来定义。

主要发现

  • 慢性肝病病因患病率:酒精相关性肝病(ALD)0.85%,MetALD 3.38%,慢性乙型肝炎(CHB)0.23%,慢性丙型肝炎(CHC)0.73%,ALD合并病毒性肝炎0.16%,MASLD 33.05%。
  • 普通人群肝硬化患病率:ALD肝硬化0.08%,MetALD肝硬化0.19%,CHB肝硬化0.01%,CHC肝硬化0.10%,MASLD肝硬化1.27%,ALD合并病毒性肝炎肝硬化0.08%,其他肝硬化0.87%。
  • 慢性肝病中临床显著门静脉高压患病率:MetALD 1.31%,CHB 1.60%,CHC 4.73%,MASLD 2.00%,对照组0.35%,总体人群患病率0.98%。
  • 多变量分析中,过量饮酒、CHC、男性、肥胖、2型糖尿病和高血压与肝硬化风险增加独立相关(均p<0.05)。
  • 慢性肝病中临床显著门静脉高压的预测因素包括CHC、肥胖和2型糖尿病(均p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: There is a paucity of data about the prevalence of cirrhosis and portal hypertension in the US general population. APPROACH AND RESULTS: We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcohol-associated liver disease (ALD), MetALD, viral hepatitis to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD). Cirrhosis was evaluated using liver stiffness measurement by transient elastography or FIB-4 score; CS-portal hypertension was defined through liver stiffness measurement and platelet count or the use of nonselective beta-blockers in the presence of cirrhosis.The prevalence of chronic liver disease etiologies was ALD 0.85%, MetALD 3.38%, CHB 0.23%, CHC 0.73%, ALD + viral hepatitis 0.16%, and MASLD 33.05%. In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%. The prevalence of CS-portal hypertension in chronic liver disease was 1.31% in MetALD, 1.60% in CHB, 4.73% in CHC, 2.00% in MASLD, and 0.35% in controls, to yield a population prevalence of 0.98%. In multivariate analysis, excessive alcohol use, CHC, male sex, obesity, type 2 diabetes, and hypertension were independently associated with an increased risk of cirrhosis (all p <0.05). Predictors of having CS-portal hypertension in chronic liver disease included CHC, obesity, and type 2 diabetes (all p <0.05). CONCLUSIONS: The prevalence of cirrhosis in the United States is 2.6% while the prevalence of CS-portal hypertension is 0.98%. Individuals with MASLD comprise the majority of US residents with cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, de Avila L, Racila A, et al. Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology. 2025. PMID: 39879587. doi:10.1097/HEP.0000000000001243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。